KBC Group NV Increases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

KBC Group NV lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 80.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,198 shares of the biotechnology company’s stock after buying an additional 4,537 shares during the quarter. KBC Group NV’s holdings in BioCryst Pharmaceuticals were worth $77,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,322 shares during the period. Captrust Financial Advisors grew its holdings in BioCryst Pharmaceuticals by 19.4% in the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,644 shares during the period. Creative Planning grew its holdings in BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares during the period. SkyView Investment Advisors LLC grew its holdings in BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 3,000 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in BioCryst Pharmaceuticals by 7.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 51,012 shares of the biotechnology company’s stock worth $388,000 after purchasing an additional 3,653 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $8.72 on Monday. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -14.29 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $9.00. The company’s fifty day moving average price is $7.72 and its 200-day moving average price is $7.73.

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of recent research reports. Needham & Company LLC upped their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays upped their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, JMP Securities restated a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.